UNSPSC 51333511: Preclamol hydrochloride

This classification denotes an antipsychotic agent with the molecular formula C14H21NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q8W2T87WWW, chemically known as phenol, 3-(1-propyl-3-piperidinyl)- but more generally known as preclamol hydrochloride, which bears US NIH Compound Identifier 55445. Most nations, for tariff and trade purposes, schedule preclamol hydrochloride under HS 29333999. As of Q4 2014, PRECLAMOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CCCN1CCC[C@H](C1)C2CCCC(C2)O.CL.

UNSPSC 51333511 Preclamol hydrochloride is a Commodity code that nominally identifies a single pharmaceutical product, but recent state and local activity under this code shows no purchases of preclamol hydrochloride itself. Instead, issuing bodies are tagging broader pharmaceutical and health-supply procurement initiatives with this code, creating a mismatch between the code's nominal scope and actual solicitation content. The recent opportunities posted under this code involve naloxone and drug deactivation systems, generic multi-source pharmaceuticals distributed through cooperative purchasing, and exploratory direct-to-manufacturer pharmacy benefit programs — none of which align with preclamol hydrochloride procurement. State and local buyers soliciting under this code include county health systems, state health and human services departments, and multistate cooperative purchasing alliances, but the activity reflects a broader pharmaceutical supply and pharmacy benefit management scope rather than procurement of the specific active pharmaceutical ingredient the code nominally describes.

Geographic activity appears concentrated in the Southeast and Midwest. Seminole County, Florida posted an IFB in July 2026 for naloxone and drug deactivation systems through an annual competitive bidding process (IFB60459723LAS, response deadline July 26, 2023); the Texas Health and Human Services Commission issued an RFI in April 2026 exploring direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (administered by the Minnesota Department of Administration) released an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities, with proposals due March 26, 2026. The mismatch between the code name and actual procurement scope suggests that either this code is being misapplied in tagging state and local opportunities, or the opportunities themselves are pharmaceutical commodities that fall outside preclamol hydrochloride's specific chemical identity. Either way, the code shows little relevant recent activity for vendors supplying preclamol hydrochloride as a distinct product line.